Vera Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.92M, a 313.36% increase year-over-year.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $2.50M, a 154.68% increase year-over-year.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $31.00K, a 93.86% decline year-over-year.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $464.00K, a 86.51% decline year-over-year.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $5.66M, a 55.98% decline from fiscal 2024.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $12.87M, a 1547.63% increase from fiscal 2023.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $781.00K, a 56.42% decline from fiscal 2022.
- Vera Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.79M, a 225.82% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.92M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $2.50M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $5.66M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $31.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $464.00K 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $982.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $12.87M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $505.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $3.44M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $6.61M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $781.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $197.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $432.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $65.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $1.79M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $853.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $47.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $65.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $550.00K 10-K · filed 2023-03-28 | |
| 2021-06-30 | $208.00K 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $342.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $282.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | |
| 2020-03-31 | $15.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |